share_log

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144：拟议出售证券

SEC announcement ·  03/04 17:47
Moomoo AI 已提取核心信息
Arcutis Biotherapeutics, Inc. officer Matthew Richard Moore is set to sell 3,468 shares of common stock on March 4, 2024. The shares, valued at an aggregate market value of $38,568, were acquired on March 1, 2024, through a restricted stock vest from Arcutis Biotherapeutics. This transaction follows a period where no securities were sold by Moore in the past three months, as per the latest filings.
Arcutis Biotherapeutics, Inc. officer Matthew Richard Moore is set to sell 3,468 shares of common stock on March 4, 2024. The shares, valued at an aggregate market value of $38,568, were acquired on March 1, 2024, through a restricted stock vest from Arcutis Biotherapeutics. This transaction follows a period where no securities were sold by Moore in the past three months, as per the latest filings.
Arcutis Biotherapeutics, Inc.高管马修·理查德·摩尔定于2024年3月4日出售3,468股普通股。这些股票的总市值为38,568美元，于2024年3月1日通过Arcutis Biotherapeutics的限制性股票背心收购。根据最新文件，这笔交易是在摩尔在过去三个月中没有出售任何证券的时期之后进行的。
Arcutis Biotherapeutics, Inc.高管马修·理查德·摩尔定于2024年3月4日出售3,468股普通股。这些股票的总市值为38,568美元，于2024年3月1日通过Arcutis Biotherapeutics的限制性股票背心收购。根据最新文件，这笔交易是在摩尔在过去三个月中没有出售任何证券的时期之后进行的。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息